Tuesday October 17th 2017

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Conclusions: These results, in a population who better resembled real-world clinical practice in terms of concomitant diseases and medications, are consistent with previous clinical trials and confirmed that the first dose administration of fingolimod is generally safe and well tolerated.Trial registration: EudraCT 2011-000770-60 (Source: BMC Neurology)

Link: 

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Leave a Comment

More from category

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms [Read More]

All you need to know about dysesthesia
All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

Medical News Today: All you need to know about dysesthesia
Medical News Today: All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

MRI brain scans can reveal MS risk in children before clinical symptoms appear
MRI brain scans can reveal MS risk in children before clinical symptoms appear

By the time multiple sclerosis (MS) is diagnosed in children, it may be difficult to prevent the disabilities and [Read More]

Open Enrollment for Marketplace and Medicare Plans
Open Enrollment for Marketplace and Medicare Plans

/About-the-Society/News/Open-Enrollment-for-Marketplace-and-Medicare-Plans [Read More]